ACROSTIC: Alveolar Cleft Repair Using Osteoinductive Ceramics

Sponsor
UMC Utrecht (Other)
Overall Status
Recruiting
CT.gov ID
NCT05331456
Collaborator
Radboud University Medical Center (Other), Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Other), Academisch Ziekenhuis Groningen (Other)
60
4
2
32.1
15
0.5

Study Details

Study Description

Brief Summary

In this study, patients with unilateral cleft lip and palate are enrolled in a multicenter stepped wedge randomized trial ithat compares alveolar cleft closure using autologous bone harvested form the mandibular symphysis with an osteoinductive biphasic calcium phosphate putty.

Condition or Disease Intervention/Treatment Phase
  • Device: Unilateral alveolar cleft repair
N/A

Detailed Description

Rationale: Patients who undergo alveolar cleft grafting have to deal with postoperative pain and comorbidity due to harvesting of autologous bone.

Objective: To evaluate if using calcium phosphate based scaffolds for alveolar cleft grafting is as effective as the use of an autologous bone graft.

Study design: A 'stepped wedge' randomized controlled trial will be conducted by four centres.

Study population: Children between the ages of 8 to 12 years with a unilateral alveolar cleft.

Intervention: Study group undergoes alveolar cleft grafting with the use of a calcium phosphate based scaffold, the control group undergoes the same procedure, but with the use of an autologous chin bone graft.

Main study parameters/endpoints: Main study outcome is one year postoperative residual bone volume in the reconstructed alveolar cleft. Secondary objectives of importance are postoperative pain and eruption of the tooth adjacent to the cleft through the reconstructed area.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients in the control group will undergo a procedure that is currently seen as the gold standard. Patients in the study group will undergo the exact same risks as the control group, except there is no risk for donor site morbidity and postoperative pain is significantly less. Postoperative clinical and radiological evaluation of both groups is according to current treatment standards.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Stepped wedge cluster randomized trialStepped wedge cluster randomized trial
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Alveolar Cleft Repair Using Osteoinductive Ceramics in Children With Unilateral Cleft Lip and Palate
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2025
Anticipated Study Completion Date :
Feb 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Other: Alveolar cleft repair using autologous bone from the mandibular symphysis

Device: Unilateral alveolar cleft repair
Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty

Other: Alveolar cleft repair using a biphasic clacium phosphate putty

Device: Unilateral alveolar cleft repair
Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty

Outcome Measures

Primary Outcome Measures

  1. Bone volume [1 year postoperatively]

    One year postoperative residual bone volume

Secondary Outcome Measures

  1. Postoperative pain [Day 1 to 7 postoperatively]

    Postoperative pain on a 1 to 10 scale

  2. Canine eruption [1 year postoperatively]

    Eruption of the canine (or lateral incisor) adjacent to the alevolar cleft

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years to 12 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • unilateral alveolar cleft, early secondary alveolar cleft closure
Exclusion Criteria:
  • cleft lip and palate in a syndromic context

Contacts and Locations

Locations

Site City State Country Postal Code
1 Amsterdam UMC Amsterdam Netherlands
2 UMC Groningen Groningen Netherlands
3 Radboud UMC Nijmegen Netherlands
4 UMC Utrecht Utrecht Netherlands

Sponsors and Collaborators

  • UMC Utrecht
  • Radboud University Medical Center
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Academisch Ziekenhuis Groningen

Investigators

  • Principal Investigator: Nard Janssen, MD, DDS, PhD, UMC Utrecht

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nard Janssen, N.G. Janssen, Prinicpal Investigator, UMC Utrecht
ClinicalTrials.gov Identifier:
NCT05331456
Other Study ID Numbers:
  • NL75562.041.21
First Posted:
Apr 15, 2022
Last Update Posted:
Apr 29, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Nard Janssen, N.G. Janssen, Prinicpal Investigator, UMC Utrecht
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 29, 2022